Skip to main content

Table 3 Vaginal stenosis (CTCAE v3.0 scale) after 12 months (n = 142)

From: Topical estrogen, testosterone, and vaginal dilator in the prevention of vaginal stenosis after radiotherapy in women with cervical cancer: a randomized clinical trial

Vaginal stenosis after radiotherapy Vaginal stenosis after 12 months Total p-value*
0 1 2
Testosterone      p < 0.01a
 0 1 (3.57%) 6 (21.43%) 2 (7.14%) 9 (32.14%)  
 1 0 (0.00%) 10 (35.71%) 6 (21.43%) 16 (57.14%)
 2 0 (0.00%) 0 (0.00%) 3 (10.71%) 3 (10.71%)
Total 01 (3.57%) 16 (57.14%) 11 (39.29%) 28 (100.00%)  
Estrogen      P < 0.01b
 0 1 (2.44%) 8 (19.51%) 0 (0.00%) 9 (21.95%)  
 1 0 (0.00%) 20 (48.78%) 10 (24.39%) 30 (73.17%)
 2 0 (0.00%) 1 (2.44%) 1 (2.44%) 2 (4.88%)
Total 1 (2.44%) 29 (70.72%) 11 (26.83%) 41 (100.00%)  
Vaginal dilator      p = 0.372c
 0 1 (3.70%) 2 (7.41%) 1 (3.70%) 4 (14.81%)  
 1 1 (3.70%) 15 (55.56%) 4 (14.81%) 20 (74.07%)
 2 0 (0.00%) 1 (3.70%) 2 (7.41%) 3 (11.11%)
Total 2 (7.41%) 18 (66.67%) 7 (25.93%) 27 (100.00%)  
Lubricant gel      P < 0.01d
 0 2 (4.35%) 7 (15.22%) 3 (6.52%) 12 (26.09%)  
 1 0 (0.00%) 21 (45.65%) 9 (19.57%) 30 (65.22%)
 2 0 (0.00%) 3 (6.52%) 1 (2.17%) 4 (8.70%)
Total 2 (4.35%) 31 (67.39%) 13 (28.26%) 46 (100.00%)  
  1. *Symmetry test a S = 14.00; GL = 3; b S = 15.36; GL = 3; c S = 3.13; GL = 3; d S = 13.00; GL = 3